Dr. Agarwal's Eye Hospital Receives ICRA AA- Credit Rating Assignment

1 min read     Updated on 23 Feb 2026, 08:45 PM
scanx
Reviewed by
Suketu GScanX News Team
Overview

Dr. Agarwal's Eye Hospital Limited received credit rating assignments from ICRA Limited on February 23, 2026, covering debt facilities worth ₹140.00 crore. The rating agency assigned ICRA AA- (Stable) rating to an ₹85.80 crore long-term loan from Axis Bank and ₹54.20 crore unallocated limits with ICRA AA- (Stable)/ICRA A1+ ratings. The company disclosed this development to BSE Limited under SEBI's listing regulations.

33405306

*this image is generated using AI for illustrative purposes only.

Dr. Agarwal's Eye Hospital Limited has announced the assignment of credit ratings by ICRA Limited for its debt facilities. The rating agency communicated its decision to the company on February 23, 2026, covering multiple banking facilities totaling ₹140.00 crore.

Credit Rating Details

ICRA Limited has assigned specific ratings to the company's banking arrangements with detailed facility-wise breakdowns. The ratings reflect the agency's assessment of the company's creditworthiness and repayment capacity across different debt instruments.

Bank Facility Bank Amount (₹ in Crores) Rating Rating Action
Long Term Loan Axis Bank Limited 85.80 ICRA AA- (Stable) Assigned
Long-Term/Short-Term Unallocated limits - 54.20 ICRA AA- (Stable)/ICRA A1+ Assigned

Rating Significance

The ICRA AA- (Stable) rating indicates high credit quality with very low credit risk. The stable outlook suggests that the rating is unlikely to change in the near term. For short-term facilities, the ICRA A1+ rating represents the highest degree of safety regarding timely payment of financial obligations.

Regulatory Compliance

The company has disclosed this credit rating assignment to BSE Limited in accordance with Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Meenakshi Jayaraman signed the disclosure document on February 23, 2026.

Banking Relationship

The primary facility covered under this rating assignment is with Axis Bank Limited, which has extended an ₹85.80 crore long-term loan to the company. The unallocated limits of ₹54.20 crore provide additional financial flexibility for the company's operational and strategic requirements.

Historical Stock Returns for Dr. Agrawals Eye Hospital

1 Day5 Days1 Month6 Months1 Year5 Years
-1.59%-2.76%-4.47%+2.44%+10.09%+1,133.13%
Dr. Agrawals Eye Hospital
View Company Insights
View All News
like17
dislike

Dr. Agarwal's Eye Hospital Announces Q3FY26 Results: Revenue ₹118.22 Crores

1 min read     Updated on 03 Feb 2026, 03:16 PM
scanx
Reviewed by
Radhika SScanX News Team
Overview

Dr. Agarwal's Eye Hospital Limited reported strong Q3FY26 financial results with revenue reaching ₹118.22 crores, representing a 24.31% year-on-year growth, while net profit surged 66.15% to ₹17.28 crores. The nine-month performance also showed robust growth with revenue of ₹350.86 crores and net profit of ₹53.86 crores. Additionally, the company announced the relocation of its registered office within Chennai to enhance administrative efficiency.

31657598

*this image is generated using AI for illustrative purposes only.

Dr. Agarwal's Eye Hospital Limited has announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating solid performance across key metrics. The specialized eye care provider also announced the relocation of its registered office within Chennai to facilitate better administrative convenience and infrastructure requirements.

Q3FY26 Financial Performance

The company's third quarter performance for FY26 shows steady growth compared to the corresponding period in the previous year, with improvements in revenue and profitability metrics.

Financial Metric: Q3FY26 Q3FY25 Growth (%)
Revenue from Operations: ₹118.22 crores ₹95.11 crores +24.31%
Net Profit After Tax: ₹17.28 crores ₹10.40 crores +66.15%
EBITDA: ₹37.14 crores ₹27.93 crores +32.98%
Profit Before Tax: ₹23.45 crores ₹14.06 crores +66.79%

Nine Months Performance FY26

For the nine months ended December 31, 2025, the company maintained strong momentum with significant year-on-year improvements across all major financial parameters.

Parameter: 9M FY26 9M FY25 Growth (%)
Revenue from Operations: ₹350.86 crores ₹297.32 crores +18.01%
Net Profit After Tax: ₹53.86 crores ₹38.66 crores +39.31%
EBITDA: ₹115.83 crores ₹91.90 crores +26.05%
Earnings Per Share (Basic): ₹113.46 ₹82.26 +37.94%

Corporate Development

The Board of Directors approved the shifting of the company's registered office within the local limits of Chennai. The registered office will be relocated from 3rd Floor, Buhari Towers, No.4, Moores Road, Off. Greams Road, Chennai, Tamil Nadu- 600 006 to 6th Floor, 1st Main Road, Austin Nagar, Alwarpet, Chennai, Tamil Nadu 600 018 with effect from February 05, 2026.

Board Meeting and Compliance

The Board of Directors meeting was held on February 03, 2026, where they approved the unaudited financial results along with the limited review report from statutory auditors. The meeting commenced at 02:00 p.m. and concluded at 02:55 p.m. The financial results will be published in newspapers in compliance with SEBI regulations and are available on the company's website at www.dragarwal.com .

Historical Stock Returns for Dr. Agrawals Eye Hospital

1 Day5 Days1 Month6 Months1 Year5 Years
-1.59%-2.76%-4.47%+2.44%+10.09%+1,133.13%
Dr. Agrawals Eye Hospital
View Company Insights
View All News
like20
dislike

More News on Dr. Agrawals Eye Hospital

1 Year Returns:+10.09%